Compare ALG & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | RARE |
|---|---|---|
| Founded | 1955 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 1996 | 2013 |
| Metric | ALG | RARE |
|---|---|---|
| Price | $150.12 | $22.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $225.00 | $59.10 |
| AVG Volume (30 Days) | 196.8K | ★ 1.5M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $1,603,715,000.00 | $673,000,000.00 |
| Revenue This Year | $5.26 | $13.12 |
| Revenue Next Year | $3.97 | $37.80 |
| P/E Ratio | $63.39 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $145.76 | $18.29 |
| 52 Week High | $233.29 | $40.17 |
| Indicator | ALG | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 38.01 |
| Support Level | $145.76 | $20.11 |
| Resistance Level | $156.54 | $23.44 |
| Average True Range (ATR) | 4.78 | 1.09 |
| MACD | 0.50 | -0.32 |
| Stochastic Oscillator | 37.38 | 13.30 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.